San Jose, CA – According to filings with the U.S. Securities and Exchange Commission, Mendel.ai is raising $12,681,920.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Karim Galil played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Mendel.ai
At Mendel.ai, our mission is to use our novel AI aided by clinical experts to streamline global oncology research by organizing real world data and automating clinical trials. We build software to solve problems at each stage of the clinical trial process, from feasibility to post-trial pharmacovigilance. We strive for excellency, to be authentic and original, and to make a difference by greeting our challenges head on.

To learn more about Mendel.ai, visit http://www.mendel.ai/

Contact:
Karim Galil, Chief Executive Officer
877-620-9080
karim@mendel.ai
https://www.linkedin.com/in/karim-galil-m-d-83a2b258/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved